Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer
- 15 January 1994
Abstract
Background. A Phase I trial was performed to determine the maximum tolerated dose of concurrent preoperative radiation therapy (5040 cGy) and 2 cycles (bolus daily times 5) of 5-fluorouracil (5-FU) and low-dose leucovorin (LV) (20 mg/m2), followed by surgery and 10 cycles of postoperative 5-FU/LV in patients with primary or recurrent rectal cancer. Methods. Twenty-four patients were entered into the study. Preoperatively, the initial dose of 5-FU was 325 mg/m2. 5-FU was escalated 50 mg/m2, while the dose of LV and radiation therapy remained constant. Chemotherapy and radiation began concurrently on day 1. The postoperative chemotherapy was not dose escalated; 5-FU, 425 mg/m2, and LV, 20 mg/m2. The median follow-up was 10 months (range, 4–19 months). Results. The resectability rate with negative margins in the 23 patients who underwent surgery was 100%. One patient refused surgery. The pathologic complete response rate was 13% (3 of 23). An additional four patients had negative nodes and a microscopic foci of tumor in the bowel wall. Therefore, the total clinical complete response rate was 30% (7 of 23). The maximum tolerated dose of 5-FU for the preoperative combined modality segment was 375 mg/m2; therefore, the recommended Phase II dose level is 325 mg/m2. The incidence of Grade 3+ toxicity for the 22 patients treated at the recommended 5-FU dose level (325 mg/m2) during the preoperative combined modality segment was as follows: diarrhea, 14%; erythema, 5%; hematologic, 10%; and total, 18%. The median nadir counts were leukocyte count, 3.7 (range, 1.5–5.9); hemoglobin count, 12.2 (range, 10.2–14.3); and platelet count (times 1000), 165 (range, 92–237). Conclusions. With this regimen, the recommended doses of chemotherapy in the combined modality segment are slightly higher than those recommended in arm 2 of the Intergroup postoperative adjuvant rectal trial 0114. This regimen will serve both as the preoperative arm of the Intergroup randomized trial of preoperative versus postoperative combined modality therapy for resectable rectal cancer (INT R9401) as well as the basis for the combined modality segment of NSABP RO-3.Keywords
This publication has 16 references indexed in Scilit:
- Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable recta cancerInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Preoperative concurrent 5-fluorouracil infusion, mitomycin c and pelvic radiation therapy in tethered and fixed rectal carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Phase I/II trial of pre-operative radiation therapy and coloanal anastomosis in distal invasive resectable rectal cancerInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Phase i trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancerInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach.Journal of Clinical Oncology, 1992
- Combined radiation therapy, mitomycin C, and 5-fluorouracil for locally recurrent rectal carcinoma: Results of a pilot studyInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Radiation therapy for unresectable rectal cancerInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Neoadjuvant chemotherapy and surgery of cancer of the esophagusSeminars in Surgical Oncology, 1986
- Preoperative irradiation for unresectable rectal and rectosigmoid carcinomasCancer, 1983
- Effect of preoperative irradiation on resectability of colorectal carcinomasInternational Journal of Radiation Oncology*Biology*Physics, 1982